BioWorld

April 10, 2002

Roche Paying Isotechnika Up To $215M For Transplantation Drug

Hoffmann-La Roche Inc. agreed to spend upward of $215 million in a global partnership with Isotechnika Inc. to develop a transplantation drug with blockbuster potential. (BioWorld Today) Read More

AEterna Seeks Acquisitions In Cancer Following C$57M Financing

Subterranean Naked Mole-Rats’ All-Purpose Incisors Neuronally Sensed In Huge Neocortex Area

Hyseq Raises $15M Privately To Develop Proprietary Drugs

Other News To Note

ImClone Presents Preclinical Data Of Erbitux In Combination Study

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...